Search - tctmd.com

Displaying 101 - 120 of 150

Sort: Relevancy | Date

News Daily News

Un Análisis Conjunto a Nivel del Paciente Avala el Uso de Bivalirudina en PCI Primarias

Yael L. Maxwell

January 12, 2015

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation TCT 2014

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Presenter: Dimitrios Alexopoulos

September 14, 2014

News Daily News

心脏肌钙蛋白T极限值可预测PCI后死亡率

August 20, 2014

News Daily News

El Umbral de Troponina T Cardíaca Predice la Mortalidad Post-PCI

August 20, 2014

News Daily News

Cardiac Troponin T Threshold Predicts Mortality After PCI

August 20, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

Presentation

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Presenter: Philippe Généreux

April 02, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

News Industry News

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

March 27, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

News Daily News

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Yael L. Maxwell

February 13, 2014

Advertisement

Un Análisis Conjunto a Nivel del Paciente Avala el Uso de Bivalirudina en PCI Primarias

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: New Data from the FDA Advisory Board Panel

Cangrelor I: Data Essentials from the Champion Trials

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

心脏肌钙蛋白T极限值可预测PCI后死亡率

El Umbral de Troponina T Cardíaca Predice la Mortalidad Post-PCI

Cardiac Troponin T Threshold Predicts Mortality After PCI

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content